Effect of Trastuzumab Deruxtecan on QT/QTc Interval and Pharmacokinetics in HER2‐Positive or HER2‐Low Metastatic/Unresectable Breast Cancer

HER2‐targeted anticancer therapies may be associated with cardiovascular adverse events. This study evaluated effects of the HER2‐targeted antibody–drug conjugate trastuzumab deruxtecan (T‐DXd, DS‐8201a) on QT/QTc interval and its pharmacokinetics. Patients with heavily pretreated, metastatic HER2‐e...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimomura, Akihiko, Takano, Toshimi, Takahashi, Shunji, Sagara, Yasuaki, Watanabe, Junichiro, Tokunaga, Eriko, Shinkai, Tetsu, Kamio, Takahiro, Kikumori, Kunika, Kamiyama, Emi, Fujisaki, Yoshihiko, Saotome, Dan, Yamashita, Toshinari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092050/
https://www.ncbi.nlm.nih.gov/pubmed/36164935
http://dx.doi.org/10.1002/cpt.2757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092050/
https://www.ncbi.nlm.nih.gov/pubmed/36164935
http://dx.doi.org/10.1002/cpt.2757

Ejemplares similares